The FDA granted REGENXBIO's BLA Priority Review with a Prescription Drug User Fee Act ("PDUFA") target action date of November 9, 2025. Logo for NS Pharma, Inc. (PRNewsfoto/NS Pharma, Inc.) In ...

ROCKVILLE, Md., May 19, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the closure of a non-dilutive, limited recourse royalty bond agreement of up to $250 million with ...

On a per-share basis, the Rockville, Maryland-based company said it had net income of 12 cents. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by ...

Simpson, President and Chief Executive Officer of REGENXBIO. "Each of our late-stage assets is demonstrating differentiation against standard of care or available treatments, giving us a pipeline ...

RegenXBio will fill its coffers with up to $250 million by monetizing more royalty rights for Novartis-partnered Zolgensma as well as anticipated payments linked to a gene therapy nearing approval ...

ROCKVILLE, Md. (AP) — ROCKVILLE, Md. (AP) — Regenxbio Inc. (RGNX) on Monday reported first-quarter earnings of $6.1 million. On a per-share basis, the Rockville, Maryland-based company said it ...

$150 million secured at closing extends cash runway into early 2027 REGENXBIO retains additional potential non-dilutive funding opportunities, including monetization of Priority Review Voucher ...